(Q35688491)

9 August 2017

title

The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines (English)

1 reference

9 August 2017

0 references

Richard O Day

3

0 references

author name string

Christine Y Lu

series ordinal

1

1 reference

9 August 2017

Kenneth M Williams

series ordinal

2

1 reference

9 August 2017

publication date

1 March 2007

1 reference

Australia and New Zealand Health Policy

9 August 2017

published in

1 reference

9 August 2017

volume

4

1 reference

9 August 2017

page(s)

2

1 reference

Creative Commons Attribution 2.0 Generic

9 August 2017

copyright license

start time

1 March 2007

1 reference

April 2022 Public Data File from Crossref

Creative Commons Attribution 2.0 Generic

0 references

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828161

Accessing health outcome data on high-cost medicines in Australia.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828161

Swedish registers to examine drug safety and clinical issues in RA.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828161

Health economics: implications for novel antirheumatic therapies

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828161

Biological drug use: US perspectives on indications and monitoring

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828161

Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828161

Equity of access to health care: outlining the foundations for action

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828161

The impact of new biologicals in the treatment of rheumatoid arthritis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828161

Research use of linked health data--a best practice protocol

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828161

Criteria for TNF-targeted therapy in rheumatoid arthritis: estimates of the number of patients potentially eligible

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828161

A cost-effectiveness approach to drug subsidy and pricing in Australia

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828161

Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828161

Economic burden of rheumatoid arthritis: a systematic review

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828161

Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828161

The underestimated long term medical and economic consequences of rheumatoid arthritis.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828161

Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828161

Population based studies of biological antirheumatic drug use in southern Sweden: comparison with pharmaceutical sales

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828161

The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828161

Access to high cost drugs in Australia

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828161

Treating rheumatoid arthritis with tumour necrosis factor alpha blockade

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828161

Drug Prices and Value for Money

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828161

15 November 2018

BSR Biologics Registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828161

Managing pharmaceutical expenditure while increasing access. The pharmaceutical management agency (PHARMAC) experience

15 November 2018

1 reference

12 December 2020

How many patients are eligible for anti-TNF therapy in the UK?

1 reference

12 December 2020

Work disability in early rheumatoid arthritis

1 reference

12 December 2020

NICE methodological guidelines and decision making in the National Health Service in England and Wales

1 reference

12 December 2020

Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis

1 reference

12 December 2020

1 reference

12 December 2020

Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost

1 reference

12 December 2020

The subsidy of pharmaceuticals in Australia: processes and challenges

1 reference

12 December 2020

The impact of anti-TNF-alpha therapy on the nature of service provision

1 reference

12 December 2020

Identifiers

DOI

10.1186/1743-8462-4-2

1 reference

Dimensions Publication ID

9 August 2017

0 references

1 reference

9 August 2017

1 reference